Literature DB >> 25302830

Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.

Masashi Hirooka1, Yohei Koizumi, Teruki Miyake, Hironori Ochi, Yoshio Tokumoto, Fujimasa Tada, Bunzo Matsuura, Masanori Abe, Yoichi Hiasa.   

Abstract

PURPOSE: To prospectively evaluate whether the characteristics of hepatic blood flow change during the early stages of fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).
MATERIALS AND METHODS: All participants provided written informed consent, and the study protocols were approved by the institutional ethics committee. A total of 121 patients with NAFLD that was diagnosed at histologic examination were enrolled. Hepatic blood flow was measured by means of Doppler ultrasonography (US), and the ratio of arterial to portal blood flow (arterioportal ratio) was calculated. Elasticity of the spleen was measured by means of real-time tissue elastography. The elastic ratio was measured as the value in the small splenic vessel divided by the value of the splenic parenchyma. The arterioportal ratio and splenic elasticity were compared in patients with all stages of fibrosis (F0-F4) and with all levels of platelet counts. Correlations among the resistive index of the hepatic artery and that of the splenic artery, the fibrosis 4 index, hepatic elasticity, arterioportal ratio, splenic elasticity, and platelet counts were analyzed. Univariate and multivariate logistic regression analyses were performed. Correlations in patients with platelet counts greater than 200 000/μL also were analyzed.
RESULTS: The mean ± standard deviation arterioportal ratio was significantly higher at fibrosis stage 2 (2.4 ± 0.6) than at fibrosis stage 0 (1.8 ± 0.4) in patients with NAFLD (P < .01). Increased splenic stiffness at earlier stages of fibrosis also was observed in patients with NAFLD (fibrosis stage 2, 4.4 ± 2.3; fibrosis stage 0, 3.2 ± 1.9; P < .05). In patients with NAFLD with platelet counts higher than 200 000/μL, pericellular fibrosis was the only significant predictor of hepatic hemodynamic change at multivariate analysis (odds ratio, 7.17; 95% confidence interval: 1.33, 57.13; P = .021).
CONCLUSION: Change in hepatic blood flow occurred during the earliest stage of hepatic fibrosis in patients with NAFLD because of outflow block in the sinusoidal area. © RSNA, 2014.

Entities:  

Mesh:

Year:  2014        PMID: 25302830     DOI: 10.1148/radiol.14132952

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.

Authors:  Claudio Tana; Marco Tana; Stefano Rossi; Mauro Silingardi; Cosima Schiavone
Journal:  J Ultrasound       Date:  2016-03-29

Review 2.  Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease.

Authors:  Gyorgy Baffy
Journal:  Dig Dis Sci       Date:  2018-01-22       Impact factor: 3.199

3.  Correlations of Hepatic Hemodynamics, Liver Function, and Fibrosis Markers in Nonalcoholic Fatty Liver Disease: Comparison with Chronic Hepatitis Related to Hepatitis C Virus.

Authors:  Ryuta Shigefuku; Hideaki Takahashi; Hiroyasu Nakano; Tsunamasa Watanabe; Kotaro Matsunaga; Nobuyuki Matsumoto; Masaki Kato; Ryo Morita; Yousuke Michikawa; Tomohiro Tamura; Tetsuya Hiraishi; Nobuhiro Hattori; Yohei Noguchi; Kazunari Nakahara; Hiroki Ikeda; Toshiya Ishii; Chiaki Okuse; Shigeru Sase; Fumio Itoh; Michihiro Suzuki
Journal:  Int J Mol Sci       Date:  2016-09-14       Impact factor: 5.923

4.  Nonalcoholic fatty liver with a hepatic arterial buffer response strongly associated with future metabolic disease.

Authors:  Masashi Hirooka; Yohei Koizumi; Teruki Miyake; Takao Watanabe; Osamu Yoshida; Yoshio Tokumoto; Atsushi Yukimoto; Yoshiko Nakamura; Yusuke Imai; Masanori Abe; Yoichi Hiasa
Journal:  Hepatol Commun       Date:  2017-07-27

5.  Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease.

Authors:  Teruki Miyake; Sakiko Yoshida; Shinya Furukawa; Takenori Sakai; Fujimasa Tada; Hidenori Senba; Shin Yamamoto; Yohei Koizumi; Osamu Yoshida; Masashi Hirooka; Teru Kumagi; Tetsuju Niiya; Hiroaki Miyaoka; Abe Masanori; Bunzo Matsuura; Yoichi Hiasa
Journal:  Open Med (Wars)       Date:  2018-09-14

Review 6.  Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

Authors:  Wah-Kheong Chan; Soek-Siam Tan; Siew-Pheng Chan; Yeong-Yeh Lee; Hoi-Poh Tee; Sanjiv Mahadeva; Khean-Lee Goh; Anis Safura Ramli; Feisul Mustapha; Nik Ritza Kosai; Raja Affendi Raja Ali
Journal:  J Gastroenterol Hepatol       Date:  2022-02-08       Impact factor: 4.369

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.